Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis
Systematic Reviews · 2024
DOI: 10.1186/s13643-024-02653-7 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Systematic Reviews, 2024. Verfasst von Yuan Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Gansu Provincial Maternity and Child-care Hospital (Gansu Provincial Central Hospital), Lanzhou, 730000, China. Hauptthemen laut MEDLINE: Vitiligo, Pyrimidines, Pyrazoles, Nitriles. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
IMPORTANCE: Vitiligo is a chronic skin disorder causing depigmentation. There is a lack of evidence-based medical evidence regarding ruxolitinib efficacy and safety for vitiligo. OBJECTIVE: To assess the efficacy and safety of ruxolitinib cream in the treatment of vitiligo. METHODS: The databases of PubMed, Embase, and Cochrane Library were searched. The literature screening was independently conducted by two reviewers. DATA EXTRACTION AND SYNTHESIS: For continuous variables, weighted mean difference (WMD) along with a 95% confidence interval (CI) was performed. For dichotomous outcomes, we calculated the odds ratios (ORs) or risk ratios (RRs), and their corresponding 95% CIs. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). MAIN OUTCOMES AND MEASURES: Symptoms, quality of life, and safety were evaluated using various measures, including the Facial Vitiligo Area Scoring Index (F-VASI), Total Vitiligo Area Scoring Index (T-VASI), Facial Body Surface Area (F-BAS), Total Body Surface Area (T-BAS) and Treatment-emergent Adverse Events (TEAEs). RESULTS: Three trials, involving a total of 830 participants from nine countries were included (female 388, 46.7%, male 442, 53.3%). The meta-analysis demonstrated a significant increase in the likelihood of participants achieving F-VASI75 (OR, 4.34 [95% CI 2.67-7.06]; high), F-VASI50 (OR 4.71 [95% CI 3.24-6.84]; high), T-VASI75 (OR 2.78 [95% CI 1.10-7.00]; moderate), and T-VASI50 (OR 4.47 [95% CI 2.52-7.92]; high) when compared ruxolitinib to vehicle. Ruxolitinib was associated with more lowered percentage change of F-VASI scores (MD - 32.79 [95% CI - 36.37 to - 29.21]; moderate), and T-VASI scores (MD - 20.22 [95% CI - 23.11 to - 17.33]; moderate) from baseline compared to vehicle. There may not be a significant difference in the occurrence of TEAEs between ruxolitinib and vehicle (RR 1.46 [95% CI 0.85-2.49]; high). CONCLUSIONS: The findings suggest that ruxolitinib cream holds promise as a treatment option for vitiligo. Further long-term studies are needed to assess its sustained efficacy and safety profile. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023431112.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Gansu Provincial Maternity and Child-care Hospital (Gansu Provincial Central Hospital), Lanzhou, 730000, China.
- School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau SAR, China.
- Department of Pharmacy, Beijing Hospital (National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences), NO.1 Da Hua Road, Dong Dan, Beijing, 100730, China.
- Department of Pharmacy, China, Aerospace Science & , Industry Corporation 731 Hospital, Beijing, 100074, China.
- Department of Pharmacy, Beijing Hospital (National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences), NO.1 Da Hua Road, Dong Dan, Beijing, 100730, China. sxl1220@163.com.
Zitieren
APA
Yuan, Y., Zhang, Y., Zheng, L., Gu, X., Yu, S., & Sun, X. (2024). Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis. Systematic Reviews. https://doi.org/10.1186/s13643-024-02653-7
Vancouver
Yuan Y, Zhang Y, Zheng L, Gu X, Yu S, Sun X. Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis. Systematic Reviews. 2024. doi:10.1186/s13643-024-02653-7
BibTeX
@article{Yuan2024,
author = {Yuan, Yuan and Zhang, Yatong and Zheng, Li and Gu, Xiaotong and Yu, Shaohua and Sun, Xuelin},
title = {Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis},
journal = {Systematic Reviews},
year = {2024},
doi = {10.1186/s13643-024-02653-7}
}
EUVIMED